Covenant Partners’s Castle Biosciences CSTL Stock Holding History

Covenant Partners’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,279	Closed	-$483K	–	183
2023 Q1	$483K	Hold	21,279	–	–	0.19%	92
2022 Q4	$501K	Hold	21,279	–	–	0.2%	85
2022 Q3	$555K	Hold	21,279	–	–	0.27%	69
2022 Q2	$467K	Hold	21,279	–	–	0.22%	93
2022 Q1	$955K	Hold	21,279	–	–	0.38%	48
2021 Q4	$912K	Hold	21,279	–	–	0.34%	60
2021 Q3	$1.42M	Hold	21,279	–	–	0.56%	30
2021 Q2	$1.56M	Hold	21,279	–	–	0.59%	24
2021 Q1	$1.46M	Sell	21,279 -9,329	-30%	-$701K	0.58%	24
2020 Q4	$2.06M	Hold	30,608	–	–	0.87%	16
2020 Q3	$1.57M	Sell	30,608 -21,504	-41%	-$957K	0.76%	17
2020 Q2	$1.96M	Sell	52,112 -3,232	-6%	-$110K	0.91%	17
2020 Q1	$1.65M	Buy	+55,344	New	+$1.67M	0.88%	16

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Covenant Partners's CSTL Position: Q2 2023 in Review

Covenant Partners sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 21,279 shares — an estimated $483K sold.

Covenant Partners first reported a position in CSTL in Q1 2020 and held it in 13 quarters. The position peaked at $2.06M in Q4 2020. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

Covenant Partners reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
Covenant Partners sold 21,279 Castle Biosciences shares in Q2 2023, an estimated $483K.
Covenant Partners first reported a position in Castle Biosciences in Q1 2020 and held it in 13 quarters.
Covenant Partners's Castle Biosciences position peaked at $2.06M in Q4 2020.
130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Covenant Partners's 13F filing for Q2 2023, filed 11 Aug 2023.